[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse VNN1

Summary
SymbolVNN1
Namevanin 1
Aliases Tiff66; HDLCQ8; pantetheine hydrolase; vanin-1; vannin 1; vascular non-inflammatory molecule 1
Chromosomal Location6q23-q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Lipid-anchor, GPI-anchor
Domain PF00795 Carbon-nitrogen hydrolase
Function

Amidohydrolase that hydrolyzes specifically one of the carboamide linkages in D-pantetheine thus recycling pantothenic acid (vitamin B5) and releasing cysteamine.

> Gene Ontology
 
Biological Process GO:0002521 leukocyte differentiation
GO:0002526 acute inflammatory response
GO:0002544 chronic inflammatory response
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0006732 coenzyme metabolic process
GO:0006766 vitamin metabolic process
GO:0006767 water-soluble vitamin metabolic process
GO:0006768 biotin metabolic process
GO:0006979 response to oxidative stress
GO:0007159 leukocyte cell-cell adhesion
GO:0008631 intrinsic apoptotic signaling pathway in response to oxidative stress
GO:0015939 pantothenate metabolic process
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030098 lymphocyte differentiation
GO:0030217 T cell differentiation
GO:0033077 T cell differentiation in thymus
GO:0033081 regulation of T cell differentiation in thymus
GO:0033089 positive regulation of T cell differentiation in thymus
GO:0034599 cellular response to oxidative stress
GO:0036473 cell death in response to oxidative stress
GO:0042110 T cell activation
GO:0045580 regulation of T cell differentiation
GO:0045582 positive regulation of T cell differentiation
GO:0045619 regulation of lymphocyte differentiation
GO:0045621 positive regulation of lymphocyte differentiation
GO:0045785 positive regulation of cell adhesion
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0051186 cofactor metabolic process
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071593 lymphocyte aggregation
GO:0071594 thymocyte aggregation
GO:0097193 intrinsic apoptotic signaling pathway
GO:1900407 regulation of cellular response to oxidative stress
GO:1900408 negative regulation of cellular response to oxidative stress
GO:1902105 regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1902175 regulation of oxidative stress-induced intrinsic apoptotic signaling pathway
GO:1902176 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway
GO:1902532 negative regulation of intracellular signal transduction
GO:1902882 regulation of response to oxidative stress
GO:1902883 negative regulation of response to oxidative stress
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903201 regulation of oxidative stress-induced cell death
GO:1903202 negative regulation of oxidative stress-induced cell death
GO:1903706 regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:2000398 regulation of thymocyte aggregation
GO:2000400 positive regulation of thymocyte aggregation
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001242 regulation of intrinsic apoptotic signaling pathway
GO:2001243 negative regulation of intrinsic apoptotic signaling pathway
Molecular Function GO:0016810 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds
GO:0016811 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides
GO:0017159 pantetheine hydrolase activity
Cellular Component GO:0031225 anchored component of membrane
> KEGG and Reactome Pathway
 
KEGG hsa00770 Pantothenate and CoA biosynthesis
Reactome R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-1430728: Metabolism
R-HSA-392499: Metabolism of proteins
R-HSA-196854: Metabolism of vitamins and cofactors
R-HSA-196849: Metabolism of water-soluble vitamins and cofactors
R-HSA-6798695: Neutrophil degranulation
R-HSA-163125: Post-translational modification
R-HSA-597592: Post-translational protein modification
R-HSA-199220: Vitamin B5 (pantothenate) metabolism
Summary
SymbolVNN1
Namevanin 1
Aliases Tiff66; HDLCQ8; pantetheine hydrolase; vanin-1; vannin 1; vascular non-inflammatory molecule 1
Chromosomal Location6q23-q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between VNN1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolVNN1
Namevanin 1
Aliases Tiff66; HDLCQ8; pantetheine hydrolase; vanin-1; vannin 1; vascular non-inflammatory molecule 1
Chromosomal Location6q23-q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of VNN1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolVNN1
Namevanin 1
Aliases Tiff66; HDLCQ8; pantetheine hydrolase; vanin-1; vannin 1; vascular non-inflammatory molecule 1
Chromosomal Location6q23-q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of VNN1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2350.638
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2610.754
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2260.739
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4270.583
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.5430.22
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9860.518
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0810.897
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1480.877
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2540.831
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1440.928
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.6290.432
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6730.0111
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of VNN1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.79.6-5.90.679
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.710.2-6.50.425
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.37.4-2.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1614014.3-14.30.209
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolVNN1
Namevanin 1
Aliases Tiff66; HDLCQ8; pantetheine hydrolase; vanin-1; vannin 1; vascular non-inflammatory molecule 1
Chromosomal Location6q23-q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of VNN1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolVNN1
Namevanin 1
Aliases Tiff66; HDLCQ8; pantetheine hydrolase; vanin-1; vannin 1; vascular non-inflammatory molecule 1
Chromosomal Location6q23-q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of VNN1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by VNN1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolVNN1
Namevanin 1
Aliases Tiff66; HDLCQ8; pantetheine hydrolase; vanin-1; vannin 1; vascular non-inflammatory molecule 1
Chromosomal Location6q23-q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of VNN1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolVNN1
Namevanin 1
Aliases Tiff66; HDLCQ8; pantetheine hydrolase; vanin-1; vannin 1; vascular non-inflammatory molecule 1
Chromosomal Location6q23-q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of VNN1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolVNN1
Namevanin 1
Aliases Tiff66; HDLCQ8; pantetheine hydrolase; vanin-1; vannin 1; vascular non-inflammatory molecule 1
Chromosomal Location6q23-q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between VNN1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolVNN1
Namevanin 1
Aliases Tiff66; HDLCQ8; pantetheine hydrolase; vanin-1; vannin 1; vascular non-inflammatory molecule 1
Chromosomal Location6q23-q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting VNN1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.